ArticleScience (New York, N.Y.)2023
The evolution of two transmissible cancers in Tasmanian devils.
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Identification of expressed endogenous retroviral element associated long terminal repeats in devil facial tumour cells.Open biology · 2026Article
- Article
- Article
- Metabolic pathways fuelling devil facial tumour diseases.The FEBS journal · 2026Article
- Beyond Mice and Men: Alternative Vertebrate and Invertebrate Models in Cancer Biology.Annual review of cancer biology · 2026Article
- Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers.The EMBO journal · 2026Article
- Two kinds of evolutionary individuals: the concept of common interest as an evolutionary foundation of dualism on biological individuality.History and philosophy of the life sciences · 2026Article
- When cells rebel: a comparative genomics investigation into marsupial cancer susceptibility.Molecular biology and evolution · 2026Article
- Evolution of chromosomes and nuclear architectures of amniotes.Nature communications · 2025Article
- Boost or Bust? The Impact of Supplementation on Functional Genetic Diversity and Selective Processes in Tasmanian Devils.Molecular ecology · 2025Article
- Comparative Genomics of Sex-Determination-Related Genes Reveals Shared Evolutionary Patterns Between Bivalves and Mammals, but Not Fruit Flies.Molecular ecology · 2025Article
- Loss-of-function mutations inBiology letters · 2025Article
- Temporal Changes in Tasmanian Devil Genetic Diversity at Sites With and Without Supplementation.Molecular ecology · 2025Article
- Divergent somatic mutation patterns among human cerebellar neuron types.bioRxiv : the preprint server for biology · 2025Article
- The devil in more detail: Eco-evolutionary genomics of Tasmanian devil persistence despite range-wide spread of a fatal, transmissible cancer.PLoS pathogens · 2025Article
- Illuminating the mystery of thylacine extinction: a role for relaxed selection and gene loss.Proceedings. Biological sciences · 2025Article
- Horizontal transfer of nuclear DNA in transmissible cancer.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cathelicidin antimicrobial peptides mediate immune protection in marsupial neonates.Science advances · 2025Article
- No Evidence for Distinct Transcriptomic Subgroups of Devil Facial Tumor Disease (DFTD).Evolutionary applications · 2025Article
- Direct measurement of the male germline mutation rate in individuals using sequential sperm samples.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Tasmanian devils have spawned two transmissible cancer lineages, named devil facial tumor 1 (DFT1) and devil facial tumor 2 (DFT2). We investigated the genetic diversity and evolution of these clones by analyzing 78 DFT1 and 41 DFT2 genomes relative to a newly assembled, chromosome-level reference. Time-resolved phylogenetic trees reveal that DFT1 first emerged in 1986 (1982 to 1989) and DFT2 in 2011 (2009 to 2012). Subclone analysis documents transmission of heterogeneous cell populations. DFT2 has faster mutation rates than DFT1 across all variant classes, including substitutions, indels, rearrangements, transposable element insertions, and copy number alterations, and we identify a hypermutated DFT1 lineage with defective DNA mismatch repair. Several loci show plausible evidence of positive selection in DFT1 or DFT2, including loss of chromosome Y and inactivation of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.